{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:18Z","timestamp":1792783278168,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Penn State Department of Urology No Shave November Education and Research Fund","id":[{"id":"https:\/\/ror.org\/04p491231","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy and long-term renal function outcomes following radical nephrectomy (RN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the TriNetX Research Network, we identified adults who underwent RN between 2005 and 2025. Patients were stratified based on GLP-1 RA use in the peri-operative period. Propensity score matching (1:1) was performed to control for demographic factors, baseline laboratory parameters, and relevant comorbidities. Baseline renal function, including serum creatinine and estimated glomerular filtration rate (eGFR), was included in the matching process. Renal outcomes included acute kidney injury (AKI), chronic kidney disease (CKD) stage 3, CKD stage 4, CKD stage 5, dialysis dependence, and eGFR, assessed at 1-, 2-, and 5-year follow-up intervals. Time-to-event analyses were conducted using Kaplan\u2013Meier methods and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 3316 patients (1658) per group) were included in the final analysis. GLP-1 RA users demonstrated significantly lower AKI incidence at 1\u00a0year (6.3% vs 12.4%), 2\u00a0years (9.5% vs 16.8%), and 5\u00a0years (13.4% vs 22.1%) (all p\u2009&lt;\u20090.001). GLP-1 RA use was associated with significantly lower incidence of CKD Stage 3 (at 1\u00a0year (12.3% vs 17.2%), 2\u00a0years (15.% vs 21.7%, and 5\u00a0years (19.7%, vs 25.4%), CKD stage 4 at 1\u00a0year (3.1% vs 6.9%), 2\u00a0years (4.7% vs 9.0%), and 5\u00a0years (6.2% vs 10.9%), and CKD stage 5 at 2\u00a0years (1.2% vs 3.9%) and 5\u00a0years (1.7% vs 4.7%) (all p\u2009&lt;\u20090.001). Dialysis dependence was also markedly reduced in the GLP-1 RA cohort (2\u00a0years: 1.0% vs 5.6%; 5\u00a0years: 1.7% vs 7.3%; all p\u2009&lt;\u20090.001). Kaplan\u2013Meier analyses demonstrated improved AKI-free, advanced CKD-free, and dialysis-free survival among GLP-1 RA users, with Cox proportional hazards models confirming significantly lower hazards of AKI, advanced CKD (stage 3\u20135), and dialysis dependence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 RA therapy is associated with improved renal function outcomes following radical nephrectomy, with the most consistent benefit observed in reducing progression to advanced CKD (stage 3\u20135) and dialysis dependence. These findings support further investigation of GLP-1 RAs as a potential renal protective strategy in patients after nephrectomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-026-05177-2","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:13:52Z","timestamp":1778685232000},"page":"4195-4202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glucagon like peptide-1 receptor agonist therapy and long-term renal outcomes after radical nephrectomy: a propensity-matched cohort analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Noor Banihashem","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Saran","family":"Manivasagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"5177_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(06)70803-8","volume":"7","author":"WC Huang","year":"2006","unstructured":"Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735\u2013740. https:\/\/doi.org\/10.1016\/S1470-2045(06)70803-8","journal-title":"Lancet Oncol"},{"key":"5177_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12882-024-03601-2","volume":"25","author":"Y Yan","year":"2024","unstructured":"Yan Y, Liu Y, Li B, Xu S, Du H, Wang X, Li Y (2024) Trends and predictors of changes in renal function after radical nephrectomy for renal tumours. BMC Nephrol 25:174. https:\/\/doi.org\/10.1186\/s12882-024-03601-2","journal-title":"BMC Nephrol"},{"key":"5177_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2018.08.028","volume":"74","author":"B Gershman","year":"2018","unstructured":"Gershman B, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC (2018) Radical versus partial nephrectomy for cT1 renal cell carcinoma. Eur Urol 74:825\u2013832. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.028","journal-title":"Eur Urol"},{"key":"5177_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Gorriz JL, Soler MJ et al (2025) Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med 31:278\u2013285. https:\/\/doi.org\/10.1038\/s41591-024-03327-6","journal-title":"Nat Med"},{"key":"5177_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"5177_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide 2.4 mg once weekly in adults with overweight or obesity and type 2 diabetes (STEP 2): a randomized double-blind placebo-controlled phase 3 trial. Lancet 397:971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"5177_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00271-7","author":"S Badve","year":"2024","unstructured":"Badve S, Bilal A, Lee MMY et al (2024) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5177_CR8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"5177_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, Tonneijck L, Smits MM et al (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13:605\u2013628. https:\/\/doi.org\/10.1038\/nrneph.2017.123","journal-title":"Nat Rev Nephrol"},{"key":"5177_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.kint.2021.10.033","volume":"101","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fu EL, Clase CM et al (2022) GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type 2 diabetes. Kidney Int 101:360\u2013368. https:\/\/doi.org\/10.1016\/j.kint.2021.10.033","journal-title":"Kidney Int"},{"key":"5177_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12933-025-02649-0","volume":"24","author":"LC Lin","year":"2025","unstructured":"Lin LC, Chen JY, Huang TT, Wu VC (2025) Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients. Cardiovasc Diabetol 24:87. https:\/\/doi.org\/10.1186\/s12933-025-02649-0","journal-title":"Cardiovasc Diabetol"},{"key":"5177_CR12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1210\/jc.2010-2822","volume":"96","author":"JB Buse","year":"2011","unstructured":"Buse JB, Garber A, Rosenstock J et al (2011) Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the LEAD trials. J Clin Endocrinol Metab 96:1695\u20131702. https:\/\/doi.org\/10.1210\/jc.2010-2822","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"5177_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jdi.12464","volume":"7","author":"K Katsurada","year":"2016","unstructured":"Katsurada K, Yada T (2016) Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig 7(Suppl 1):64\u201369. https:\/\/doi.org\/10.1111\/jdi.12464","journal-title":"J Diabetes Investig"},{"key":"5177_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40620-020-00738-9","volume":"33","author":"CM Mosterd","year":"2020","unstructured":"Mosterd CM, Bjornstad P, van Raalte DH (2020) Nephroprotective effects of GLP-1 receptor agonists: where do we stand? J Nephrol 33:965\u2013975. https:\/\/doi.org\/10.1007\/s40620-020-00738-9","journal-title":"J Nephrol"},{"key":"5177_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B et al (2018) Dulaglutide versus insulin Glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre open-label randomized trial. Lancet Diabetes Endocrinol 6:605\u2013617. https:\/\/doi.org\/10.1016\/S2213-8587(18)30104-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5177_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ckj\/sfv144","volume":"9","author":"J Gameiro","year":"2016","unstructured":"Gameiro J, Neves JB, Rodrigues N et al (2016) Acute kidney injury, long-term renal function and mortality in patients undergoing major abdominal surgery: a cohort analysis. Clin Kidney J 9:192\u2013200. https:\/\/doi.org\/10.1093\/ckj\/sfv144","journal-title":"Clin Kidney J"},{"key":"5177_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173955","volume":"10","author":"A Rojano Toimil","year":"2021","unstructured":"Rojano Toimil A, Ciudin A (2021) GLP-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes. J Clin Med 10:3955. https:\/\/doi.org\/10.3390\/jcm10173955","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"5177_CR18","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1101-p","volume":"67","author":"S Kaneko","year":"2018","unstructured":"Kaneko S, Ueda Y, Tahara Y (2018) Dulaglutide has favorable outcomes in elderly or renal impairment patients with type 2 diabetes. Diabetes 67(Suppl 1):1101-P. https:\/\/doi.org\/10.2337\/db18-1101-p","journal-title":"Diabetes"},{"key":"5177_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00967","volume":"11","author":"D Kawanami","year":"2020","unstructured":"Kawanami D, Takashi Y (2020) GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms. Front Pharmacol 11:967. https:\/\/doi.org\/10.3389\/fphar.2020.00967","journal-title":"Front Pharmacol"},{"key":"5177_CR20","doi-asserted-by":"publisher","unstructured":"Jones B (2025) Perioperative management of patients on GLP-1 receptor agonists: clinical implications and best practices. Preprints 2025:2025060860. https:\/\/doi.org\/10.20944\/preprints202506.0860.v","DOI":"10.20944\/preprints202506.0860.v"},{"key":"5177_CR21","doi-asserted-by":"publisher","first-page":"F1519","DOI":"10.1152\/ajprenal.00211-2018","volume":"315","author":"BP Dieter","year":"2018","unstructured":"Dieter BP, Alicic RZ, Tuttle KR (2018) GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Renal Physiol 315:F1519\u2013F1527. https:\/\/doi.org\/10.1152\/ajprenal.00211-2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"5177_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12967-021-02976-2","volume":"19","author":"D Chae","year":"2021","unstructured":"Chae D, Kim NY, Kim KJ, Park K, Oh C, Kim SY (2021) Predictive models for chronic kidney disease after radical or partial nephrectomy in renal cell cancer using early postoperative serum creatinine levels. J Transl Med 19:307. https:\/\/doi.org\/10.1186\/s12967-021-02976-2","journal-title":"J Transl Med"},{"key":"5177_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/jcm9030619","volume":"9","author":"WH Kim","year":"2020","unstructured":"Kim WH, Shin KW, Ji SH, Jang YE, Lee JH, Jeong CW, Kwak C, Lim YJ (2020) Robust association between acute kidney injury after radical nephrectomy and long-term renal function. J Clin Med 9:619. https:\/\/doi.org\/10.3390\/jcm9030619","journal-title":"J Clin Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05177-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:53:11Z","timestamp":1789631591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05177-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5177"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05177-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was deemed exempt from IRB-approval due to the use of de-identified data and use of summary statistics alone.","order":2,"name":"Ethics","label":"Institutional review board approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}